Terms: = Brain cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
4 results:
1. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract] [Full Text] [Related]
2. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma.
Ryan SL; Schwalbe EC; Cole M; Lu Y; Lusher ME; Megahed H; O'Toole K; Nicholson SL; Bognar L; Garami M; Hauser P; Korshunov A; Pfister SM; Williamson D; Taylor RE; Ellison DW; Bailey S; Clifford SC
Acta Neuropathol; 2012 Apr; 123(4):501-13. PubMed ID: 22139329
[TBL] [Abstract] [Full Text] [Related]
3. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization.
Michiels EM; Weiss MM; Hoovers JM; Baak JP; Voûte PA; Baas F; Hermsen MA
J Pediatr Hematol Oncol; 2002; 24(3):205-10. PubMed ID: 11990307
[TBL] [Abstract] [Full Text] [Related]
4. [Pathology and biology of small cell lung cancer].
Shimosato Y
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):952-8. PubMed ID: 2839114
[TBL] [Abstract] [Full Text] [Related]
